Evidently, in such subjects the powerful IL-5R antagonism and the associated ADCC mechanism sustained by benralizumab are much more advantageous than anti-IgE therapy in providing an effective decrease in blood eosinophil count, and the consequent prevention of asthma exacerbations. Here, IL5RA is linked to asthma.